Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot2 - STU 1 ballot International flag

This page is part of the Evidence Based Medicine on FHIR Implementation Guide (v1.0.0-ballot2: STU1 Ballot 2) based on FHIR (HL7® FHIR® Standard) v6.0.0. No current official version has been published yet. For a full list of available versions, see the Directory of published versions

Example Group: InterventionDefinition: Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors

Generated Narrative: Group 236769

version: 72; Last updated: 2025-03-20 18:40:09+0000

Profile: ConceptualExposureDefinition

Artifact Author: Computable Publishing®: MAGIC-to-FEvIR Converter:

RelatesTo

  • type: part-of
  • targetReference: MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes (Identifier: FEvIR Linking Identifier/MAGIC-5288-j1Wqrn-conversion-report)

url: https://fevir.net/resources/Group/236769

identifier: FEvIR Object Identifier/https://fevir.net/FOI/236769, FEvIR Linking Identifier/MAGIC-5288-j1Wqrn-intervention-85394-I-85798

name: Sodium_Glucose_Transport_Protein_2_SGLT2_inhibitors85394_I_85798

title: InterventionDefinition: Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors

status: Active

publisher: Computable Publishing LLC

contact: support@computablepublishing.com

description:

This Group Resource is referenced in an example for the EBMonFHIR Implementation Guide.

UseContexts

-CodeValue[x]
*Evidence Based Medicine on FHIR Implementation Guide Code System evidence-communication: Evidence CommunicationConceptualExposureDefinition

copyright:

https://creativecommons.org/licenses/by-nc-sa/4.0/

membership: Conceptual